UNC-Chapel Hill researchers and industry scientists are working side by side in the same lab on Carolina’s campus to find a cure for HIV — and they’re getting closer. ViiV Healthcare and Carolina have recently announced that they have signed a second five-year, $20 million contract to continue their groundbreaking research to find a cure.
UNC-Chapel Hill researchers and industry scientists are working side by side in the same lab on Carolina’s campus to find a cure for HIV — and they’re getting closer. ViiV Healthcare and Carolina have recently announced that they have signed a second five-year, $20 million contract to continue their groundbreaking research to find a cure.
The new complex will enable further advances in its world-leading traumatic brain injury research.
Overcoming HIV latency is a major step toward creating a cure for HIV. For the first time, scientists at Carolina, Emory University and Qura Therapeutics – a partnership between Carolina and ViiV Healthcare – have found a new approach that can expose latent HIV.
UNC-Chapel Hill researchers examined how negative media coverage of the HPV vaccine impacted vaccination rates in Denmark to better understand the damage misinformation causes.
Blood clot expert Dr. Stephan Moll, professor of medicine in the School of Medicine, consulted NASA on how to treat a U.S. astronaut’s deep vein thrombosis during a mission on the International Space Station.
An alliance between UNC-Chapel Hill and Deerfield Management Company intends to advance Carolina innovations toward a possible new treatment against a devastating cancer.
